Saga Communications Q1 Net Revenue Down 15.5%. Reporting its financial data for the first quarter of 2021,
Saga Communications announces net revenue for the period was $22.3 million, a decline of 15.5% from the $26.1 million reported in Q1 of 2020. Station operating expense decreased $3.3 million to $18.9 million for the quarter compared to the same period last year. Station operating income was $4.7 million, down from the $5.5 million reported in the first quarter 0f 2020. Free cash flow increased 21.4% to $1.8 million for the quarter. Saga Communications reports net income of $758,000 in the first quarter, compared to $1.7 million in Q1 2020. The companyâs balance sheet reflects $56.3 million in cash on hand as of March 31, 2021 and $57.4 million as of May 3, 2021. Sagaâs total bank debt remained at $10 million as of the end of the first quarter 2021. Capital expenditures in the first quarter were $534,000 compared to $1 million for the same period last year. Saga
Published: Apr 29, 2021
GAITHERSBURG, Md. and SUZHOU BIOBAY, China, April 29, 2021 /PRNewswire/ Sirnaomics (Suzhou) Co. Ltd., a subsidiary of Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer, fibrotic diseases and viral infections, announced today that the company has entered into a partnership agreement with Walvax Biotechnology (Walvax) for the co-development of its anti-influenza siRNA therapeutic product candidate STP702. Sirnaomics will out-license to Walvax the exclusive development and commercialization rights for territories including mainland China, Taiwan, Hong Kong and Macao. Based on the agreement, the company will receive an initial payment of ~US$6.4 million for this asset, with additional milestone payments and royalty sharing based on product sales.
Share this article
Share this article
GAITHERSBURG, Md. and SUZHOU BIOBAY, China, April 29, 2021 /PRNewswire/ Sirnaomics Biopharmaceuticals (Suzhou) Co. Ltd., a subsidiary of Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer, fibrotic diseases and viral infections, announced today that the company has entered into a partnership agreement with Walvax Biotechnology (Walvax) for the co-development of its anti-influenza siRNA therapeutic product candidate STP702. Sirnaomics will out-license to Walvax the exclusive development and commercialization rights for territories including mainland China, Taiwan, Hong Kong and Macao. Based on the agreement, the company will receive an initial payment of ~US$6.4 million for this asset, with additional milestone payments and royalty sharing based on product sales.
Sirnaomics Enters Partnership with Walvax Biotechnology to Co-Develop Its Antiviral RNAi Therapeutic Product Candidate STP702 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.